Sunitinib, an antiangiogenic molecule, is one of the first-line standard of care in the
treatment of patients with metastatic renal cell carcinoma. However, it only benefits to a
subgroup of patients and no predictive markers of sunitinib efficacy have been identified.
Twenty-eight metastatic renal cell carcinomas were treated with sunitinib-based therapy and
another subgroup of 7 primary renal cell cancer patients were also treated by sunitinib in a
neoadjuvant trial. Measurements of CD3+ CD4+ CD25 hi Foxp3+ regulatory T cells, an …